← Back
Viridian Therapeutics, Inc.\DE
VRDN · listed on Nasdaq · worth $2.49 billion
$23.34
+2.18% on Oct 29
No insider bought Viridian Therapeutics, Inc.\DE stock in the last year. They sold it 3 times, $419K in all.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
100.8M shares
89% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider sold Viridian Therapeutics, Inc.\DE stock and none bought. None of the 3 sales is marked on its filing as planned in advance; all by company executives.
Planned sales
Form 144 notices filed for Viridian Therapeutics, Inc.\DE in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Jennifer Tousignant filed to sell 14,212 shares on 19 Aug; sold 14,212 by 19 AugNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Viridian Therapeutics, Inc.\DE, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Point72 Asset Management5.0%Aug 20
Filed by someone who owns 5% or more and does not plan to influence the company. · updateKynam Capital Management5.7%Aug 14
Filed by someone who owns 5% or more and does not plan to influence the company.State Street5.5%Aug 7
Filed by someone who owns 5% or more and does not plan to influence the company.Paradigm Biocapital Advisors LP5.1%Jun 26
All reports
Every insider trade and SEC report we hold for Viridian Therapeutics, Inc.\DE.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 27, 2025BoughtFairmount Funds Management LLCOct 27, 2025 · Traded Oct 23, 2025 · 10% owner+12%via a trust or family454,545 @ $22.00$10M
Analysts, earnings and news
Analysts' price target
$36.63 average
16 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$1.05 a share−$0.02
Q1 '26−$0.90 a share+$0.18
Q4 '25−$1.08 a share−$0.08
Q3 '25−$0.34 a share+$0.60